Clostridium difficile: Revisão sucinta da epidemiologia, diagnóstico, tratamento e controlo da infecção
Palavras-chave:
Clostridium difficile, epidemiologia, prevenção, tratamento.Resumo
Em 1935, Hall e O’Toole isolaram das fezes de recém-nascidos
saudáveis um bacilo Gram positivo anaeróbio, produtor de citotoxinas, ao qual deram o nome de Bacillus difficilis pela dificuldade na cultura e isolamento desta bactéria.1 Actualmente confrontamo-nos com dificuldades na contenção do crescimento e disseminação deste microorganismo, agora denominado de Clostridium
difficile, que é uma causa frequente de colite infecciosa nos
doentes idosos internados e submetidos a antibioterapia prévia.
Com este artigo pretendemos fazer uma revisão da epidemiologia, diagnóstico, tratamento e medidas de controlo da infecção
por Clostridium difficile.
Downloads
Referências
Ciaran PK, LaMont JT. Clostridium difficile — More Difficult Than Ever. N Engl J Med 2008;359: 1932-40.
Calfee DP. Clostridium difficile: A reemerging pathogen. Geriatrics.2008; 63 (9):10-14.
Aberra FN, Gronczewski CA, Katz JP. Clostridium difficile colitis. E-medicine, Aug 4,2009.
McDonald L, Owings M, Jernigan D. Clostridium difficile infection in patients discharged from US short-stay hospitals,1996-2003.Emerg Infect Dis. 2006;12 (3):409-415.
Loo V, Poirier L, Miller M et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.N Engl J Med.2005; 353: 2442-2449.
Mooney H. Annual incidence of MRSA falls in England, but Clostridium continues to rise.BMJ 2007; 335 (7627):958.
Muto C, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluroquinolone use. Infect Control Hosp Epidemiol.2005;26 (3):273-280.
Pépin J, Valiquete L, Cossete B. Mortality attributable to nosocomial Clostridium difficile-associated disease during epidemic caused by hypervirulent strain in Quebec. CMAJ 2005; 173 (9).
Layton B, McDonald L, Gerding D, Liedtke L, Strausbaugh L,IDSA Emerging Infections Network. Perceived increases in incidence and severity of Clostridium difficile disease: an emerging threat that continues to unfold. 15th Annual Scientific Meeting of Society for Healthcare Epidemiology of America, Los Angeles, CA April 9-12, 2005 Abstract 66 2005.
Mc Donald L, Killgore G, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med.2005;353 (23):2433-2441.
Thomas C, Stevenson M, Riley TV. Antibiotics and hospital- acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51:1339.
Wistrom J, Norrby SR, Myhre EB et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47:43.
Johnson S, Samore MH, Farrow KA et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341:1645.
Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254.
Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. J Infect Dis1977; 135 Suppl:S104.
Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974; 81:429.
Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.
Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40:1.
Carignan A, Allard C, Pepin J et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 2008; 46:1838.
Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989.
Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175:745.
Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201.
Hecker MT, Riggs MM, Hoyen CK et al. Recurrent infection with epidemic Clostridium difficile in a peripartum woman whose infant was asymptomatically colonized with the same strain. Clin Infect Dis 2008; 46:956.
Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390.
Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189.
Leung DY, Kelly CP, Boguniewicz M et al. Treatment with intravenously administered gammglobulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633.
Warny M, Vaermin JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to the clinical course of infection. Infect Immun 1994; 62:384.
Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007; 45:222.
Sambol SP, Merrigan MM, Tang JK et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002; 186:1781.
Jiang ZD, Garey KW, Price M, et al. Association of Interleukin-8 polymorphism and immunoglobulin G Anti-Toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol 2007; 5:964.
Jiang ZD, Dupont HL, Garey K et al. A Common polymorphism in the Interleukin 8 gene promoter is associated with Clostridium difficile Diarrhea. Am J Gastroenterol 2006; 101:1112.
~
Eglow R, Pothoulakis C, Itzkowitz S et al. Diminished Clostridium difficile toxin sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 1992; 90:822.
Larson HE, Barclay FE, Honour P et al. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982; 146:727.
Mardh PA, Helin I, Colleen I et al. Clostridium difficile toxin in faecal specimens of healthy children and children with diarrhoea. Acta PaediatrScand 1982; 71:275.
Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983; 148:93.
Kelly CP, Pothoulakis C, Orellana J et al. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A receptor binding. Gastroenterology 1992; 102:35.
19th ECCMID Educational Workshop: Epidemiology of Clostridium difficileinfection, Helsinki 16-19 May 2009.
Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med2000; 342:390.
McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204.
Riggs MM, Sethi AK, Zabarsky TF et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45:992.
Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002; 34:1585.
Tedesco FJ. Pseudomembranous colitis: pathogenesis and therapy. Med Clin North Am 1982; 66:655.
Rao SS, Edwards CA, Austen CJ et al. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988; 94:928.
Seppala K, Hjelt L, Supponen P. Colonoscopy in the diagnosis of antibiotic-associated colitis. Scand J Gastroenterol 1981; 16:465.
Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003; 115:543.
Bulusu M, Narayan S, Shetler K, Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000; 95:3137.
Laughon BE, Viscidi RP, Gdovin SL et al. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis 1984; 149:781.
Shanholtzer CJ, Willard KE, Holter JJ et al. Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol 1992; 30:1837.
Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007; 45:222.
Yael Waknine. FDA Approves Rapid DNA Test to Detect Clostridium difficile Infection. Medscape Medical News > Alerts, Approvals and Safety Changes > FDA Approvals. 14 Julho 2009.
Ticehurst JR, Aird DZ, Dam LM et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006; 44:1145.
Reller ME, Lema CA, Perl TM et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007; 45:3601.
Fenner L, Widmer AF, Goy G et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008; 46:328.
Fekety R, Silva J, Kaufman C et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: Comparison of two dosage regimens. Am J Med 1989; 86:15.
LaMont JT. Clinical manifestations and diagnosis of Clostridium difficile infection.Uptodate version 17.2: Maio 2009.
Tedesco FJ. Antibiotic-associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology 1979; 77:295.
Triadafilopoulos G, Hallstone AE. Acute abdomen: The first presentation of pseudomembranous colitis. Gastroenterology 1991; 101:685.
Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36:673.
Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48:598.
Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007; 45 Suppl 2:S122.
Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23:87.
ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 1998; 55:1407.
Fekety R. Guidelines for the diagnosis and management of Clostridium difficile- associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:739.
Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302.
Wenisch C, Parschalk B, Hasenhundle M et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813.
Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043.
Ciarán P K, LaMont J T.Treatment of antibiotic-associated diarrhea caused by Clostridium difficile.Uptodate version 17.2: Maio 1, 2009.
Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol1985; 80:867.
Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189.
Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758.
Hu MY, Katchar K, Kyne, L et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136:1206.
McFarland LV. Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol 2005; 54:101.
Leung DY, Kelly CP, Boguniewicz M et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633.
Aboudola S, Kotloff KL, Kyne L et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608.
Kelly CP. Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol 1996; 8:1048.
McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769.
Cohen SH. Update on IDSA practice guidelines symposium: C.difficile. Presented at the Infectious Diseases Society of America 45th Annual Meeting: San Diego, CA, October 4-7, 2007; A1165.
Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169.
Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: Case series and review of the literature. Clin Infect Dis 2002; 35:690.
Shetler K, Nieuwenhuis R, Wren SM, Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc 2001; 15:653.
Nathanson DR, Sheahan M, Chao L, Wallack MK. Intracolonic use of vancomycin for treatment of Clostridium difficile colitis in a patient with a diverted colon: Report of a case. Dis Colon Rectum 2001; 44:1871.
Sailhamer EA, Carson K, Chang Y et al. Fulminant Clostridium difficile Colitis: Patterns of care and predictors of mortality. Arch Surg 2009; 144:433.
Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980; 141:92.
Louie T, Gerson M, Grimard D et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [abstract K-425a]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society for Microbiology, 2007.
Louie TJ, Peppe J, Watt CK et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43:411.
Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359:1932.
J Siegel, E Rhinehart, M Jackson, L Chiarello, Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf
Bettin K, Clabots C, Mathie P, et al. Effectiveness of liquid soap vs. chlorhexidine gluconate for the removal of Clostridium difficile from bare hands and gloved hands. Infect Control Hosp Epidemiol 1994; 15:697.
Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1.
McDonald LC. Clostridium difficile: Responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005; 26:672.
Samore MH, Venkataraman L, DeGirolami PC et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996; 100:32.
Kim KH, Fekety R, Batts DH et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143:42.
Savage AM, Alford RH. Nosocomial spread of Clostridium difficile. Infect Control 1983; 4:31.
Larson HE, Barclay FE, Honour P, Hill ID. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982; 146:727.
Brooks SE, Veal RO, Kramer M et al. Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol 1992; 13:98.
CDC Guidelines for Environmental Infection Control in Health-Care Facilities, 2003 (http://www.cdc.gov/ncidod/dhqp/id_Cdiff_excerpts.html) Accessed August 15, 2007.
Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31:995.
Wilcox MH, Fawley WN, Wigglesworth N et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003; 54:109.
Simor AE, Bradley SF, Strausbaugh LJ et al. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002; 23:696.
Valiquette L, Cossette B, Garant MP et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45 Suppl 2:S112.
Settle CD, Wilcox MH, Fawley WN et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12:1217.
DuPont HL, Kevin G, C JP, J ZD. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control.Curr Opin Infect Dis. 2008 Oct;21(5):500-507
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
